Incyte Corporation /
Prelude Therapeutics Incorporated
Incyte secures an option on Prelude’s JAK2 program
Source for the buyer and target: Prelude Therapeutics Inc
For the buyer and target.
“On November 3, 2025, Prelude Therapeutics Incorporated (the “Company”) entered into an Exclusive Option Agreement (the “Option Agreement”) with Incyte Corporation (“Incyte”) to acquire the Company’s mutative selective JAK2V617F JH2 inhibitor program (the “Program”) for patients with myeloproliferative neoplasms (“MPNs”).”
Published 4 Nov 2025
Open the sourceWhat happened
Prelude Therapeutics Incorporated entered into an exclusive option agreement with Incyte Corporation covering Prelude’s mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms. Incyte receives the option to acquire the program and related assets. [01]
Prelude will receive $60 million in capital, comprising a $35 million cash payment and a $25 million equity investment. If Incyte exercises its option, it would pay $100 million to acquire the program. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Incyte secures an option on Prelude’s JAK2 program
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly